下一頁

有關健康專題的文章

作者負責網路醫療諮詢的問答整理

兒科相關新聞

醫療與衛生的相關評論文章

醫院與醫學教育的相關文章

評論網路流言與錯誤健康醫療觀念

醫學最新發展與消息

兒科專業非同步網路教學

來自網友對於本站的批評

記父親行誼

對於母親的思念

一、凡經行政院衛生署「健康資訊網站評獎活動」獲評為「優良健康資訊網站」者,並於93-94年連續獲選優良健康資訊網,得於獲獎網站首頁張貼「93-95年優良健康資訊網站標章」。  二、本標章係行政院衛生署頒予「93-95年度健康資訊網站評獎活動」獲獎網站之網路辨識標記,旨在表揚與彰顯獲獎網站優異之健康資訊內容與網站服務,並提供民眾在搜尋健康資訊時有所依循。然因健康資訊的日新月異,故衛生署無法對張貼本標章之網站所提供資訊之正確性與完整性時時刻刻負責。因此對於網站所刊載的內容,以及衍生的法律訴訟問題,概由網站經營者自行負責;而民眾對於網站內醫療、衛生保健等相關資訊,仍應與專業人員當面討論,以保障自身權益。  三、本標章之著作權屬行政院衛生署所有,主要提供「93-95年度健康資訊網站評獎活動」獲獎網站張貼於網站供民眾辨識之用,非經本署同意,任何網站不得私自下載與使用。

最新著作

回上一頁

流言斐語

作者:台大醫院小兒部李秉穎醫師(本文歡迎自由轉載)

建立:2014.05.14

修改:2014.05.14

Former Merck doctor predicts Gardasil will become 'greatest medical scandal of all time'

【2014.4.27 Natural News】


A top physician who used to work for drug giant Merck & Co., creator of the Gardasil vaccine for cervical cancer, has made some groundbreaking public admissions about the dangers and ineffectiveness of this controversial jab. During a recent interview with the French magazine Principes de Sante, Dr. Bernard Dalbergue confessed that Gardasil is a worthless vaccine that not only fails to protect against cervical cancer but also puts individuals at risk of paralysis, encephalitis, Guillain-Barre syndrome and a host of other debilitating ailments.

Suggesting that Gardasil will eventually become recognized as "the greatest medical scandal of all time," Dr. Dalbergue railed against its approval and continued use, claiming that "everyone" involved with it knows that it's completely worthless. Dr. Dalbergue also brought up another researcher by the name of Dr. Diane Harper who was involved with both Gardasail and Cervarix, the two approved vaccines for the human papillomavirus (HPV). As we we previously reported, Dr. Harper had previously blown the whistle on the dangers and ineffectiveness of these widely pushed vaccines.

"The full extent of the Gardasil scandal needs to be assessed," reads an English translation of the interview, which was originally published in French. "Everyone knew when this vaccine was released on the American market that it would prove to be worthless! ... In addition, decision-makers at all levels are aware of it!"

Vaccine industry, government know Gardasil is dangerous and ineffective


According to Dr. Dalbergue, industry insiders are fully aware of the fact that Gardasil can cause permanent, life-threatening damage to the central nervous system. They know that the vaccine can leave patients unable to walk, for instance, or function normally without extreme fatigue or pain. They also know that Gardasil does nothing to protect people from cervical cancer, the disease for which it is pushed aggressively on young people, both male and female.

"I predict that Gardasil will become the greatest medical scandal of all times because at some point in time, the evidence will add up to prove that this vaccine, technical and scientific feat that it may be, has absolutely no effect on cervical cancer," he stated. "[A]ll the very many adverse effects which destroy lives and even kill, serve no other purpose than to generate profit for the manufacturers."

America: a cesspool of pharmaceutical and vaccine corruption


Bringing such information to light represents a threat not only to Dr. Dalbergue's personal career, but also the careers of his former colleagues, many of whom are fully aware of all this but are likely fearful of going public with it. And for good reason, as American investigative journalist Katie Couric, who recently aired a segment discussing the adverse events associated with Gardasil, was targeted and essentially threatened into issuing a public apology for it.

Perhaps this is why Dr. Dalbergue chose to speak his mind to the French media rather than the American media. As you may already know, pharmaceutical and vaccine manufacturers have free reign in the U.S. to sell all the dangerous medicines they want to without repercussions, thanks to corrupt laws that protect them from being sued.

"U.S. law prevents anyone from suing Merck or any other vaccine manufacturer as the U.S. Congress gave them total immunity from civil lawsuits in 1986, and that legal protection which gives them a free pass to put as many vaccines into the market as they want to, was upheld by the U.S. Supreme Court in 2011," explains Health Impact News.

"In addition, the National Institute of Health receives royalties from the sales of Gardasil. So don't expect objective, true information from the U.S. mainstream media, or your U.S. doctor."

 

 

流言解析

最近,一位自稱曾經參與默沙東公司子宮頸癌疫苗Gardasil研究的法國醫師Bernard Dalbergue(註:經查,該醫師曾經任職該公司,但未直接參與Gardasil疫苗研究),在接受法國雜誌「健康原則」(Principes de Santé)訪問時,聲稱Gardasil無效又危險,並預言這將是醫藥史上最大醜聞,這一段訪問刊登在2014年4月出刊的雜誌上。

以學術專業角度來看,該訪談內容完全違背學術原則,且有違反醫學倫理之嫌。以前被視為全世界權威學者的英國Andrew Jeremy Wakefield醫師發表論文指稱麻疹-腮腺炎-德國麻疹疫苗會引起兒童自閉症,即為不實言論違反醫學倫理之一例。

Andrew Jeremy Wakefield醫師認為麻疹-腮腺炎-德國麻疹疫苗與自閉症有關的看法,造成英國、愛爾蘭的疫苗接種率大幅下降,更使這些地區蒙受好幾次麻疹與腮腺炎大流行,不但使許多兒童受害,並導致大眾對所有疫苗產生信心危機。

後來有記者發現,有人資助75萬美元給Andrew Jeremy Wakefield進行研究,而資助的人正是打算對疫苗公司提告的律師們。醫學團體對他的行為極為憤怒,英國醫務主管機關調查後,裁定威克菲爾德涉及嚴重專業失德,並撤銷他的醫生執照。

此次,法國Bernard Dalbergue指控的重點內容,翻譯成英文如下(來源:Skeptical Rapter Blog;http://www.skepticalraptor.com/skepticalraptorblog.php/antivaccine-lunatics-invent-hero/):

The full extent of the Gardasil scandal needs to be assessed: everyone knew when this vaccine was released on the American market that it would prove to be worthless! Diane Harper, a major opinion leader in the United States, was one of the first to blow the whistle, pointing out the fraud and scam of it all.

Gardasil is useless and costs a fortune! In addition, decision-makers at all levels are aware of it!

Cases of Guillain-Barré syndrome, paralysis of the lower limbs, vaccine-induced MS and vaccine-induced encephalitis can be found, whatever the vaccine.

I predict that Gardasil will become the greatest medical scandal of all times because at some point in time, the evidence will add up to prove that this vaccine, technical and scientific feat that it may be, has absolutely no effect on cervical cancer and that all the very many adverse effects which destroy lives and even kill, serve no other purpose than to generate profit for the manufacturers.

There is far too much financial interest for these medicines to be withdrawn.

子宮頸癌疫苗的正式學術名稱是人類乳突病毒疫苗(human papillomavirus vaccine),99%以上的子宮頸癌都是人類乳突病毒所引起,目前已知有數十種血清型的這類病毒都會攻擊人類。全世界的資料顯示70%的子宮頸癌是16、18兩型人類乳突病毒引起的,台灣的研究也將近60-70%,90%生殖器疣(俗稱菜花)則是由6與11型人類乳突病毒所引起。

目前已經在台灣上市使用的有兩種疫苗,葛蘭素史克藥廠製造的雙價疫苗Cervarix含有人類乳突病毒16型與18型,主要目的是預防子宮頸癌。默沙東公司製造的四價疫苗Gardasil含有人類乳突病毒6、11、16、18型,目的是預防子宮頸癌與生殖器疣。

Bernard Dalbergue在法國雜誌的訪談內容有幾個要點:
1. Gardasil無法有效預防子宮頸癌。
2. Gardasil有很多副作用,並可能致命。
3. 藥廠與所有專家都知道Gardasil的這些問題,但因為投資太大,所以不願意承認真相。

以下分析這三點指控的謬誤:

1. Bernard Dalbergue指稱疫苗「絕對無法」預防子宮頸癌,卻沒有舉出這種說法的根據為何。兩種疫苗的上市前研究跟上市後追蹤,都顯示這是有史以來最有效的疫苗!一般疫苗的保護效益在60%-90%之間,人類乳突病毒疫苗的保護效益則高達95%-100%。一般疫苗的保護效果維持5-10年,人類乳突病毒疫苗則一直到5-10年以後都沒有效果明顯下降的現象。相關的反疫苗報導中,有人提到90%以上的人類乳突病毒會自行痊癒,又說子宮頸癌發生率正在下降,根本不需要疫苗。是的,大部分病毒感染會自行痊癒,但終生潛伏的少病患會導致十幾二十年後致命的子宮頸癌。子宮頸癌發生率下降主要是醫療進步與篩檢的推廣,但即使如此,台灣每年還是有數百位女性死於子宮頸癌,相當於平均每天有兩位台灣女性因為子宮頸癌死亡!


2. 全世界接種這種疫苗的女性已超過數億,美國在2013年以前則至少接種了五千多萬劑子宮頸癌疫苗。這麼多人打疫苗,自然會發生疾病發作時間上的巧合。美國疾病管制及預防中心與世界衛生組織是兩個權威性疫苗策略建議機構,兩者都推動接種人類乳突病毒疫苗,他們也都曾經仔細評估與疫苗可能有關的不良事件,結果都沒有發現疫苗有安全性的問題。不打疫苗的人同樣會出現像Bernard Dalbergue提到的那些疾病,而Bernard Dalbergue先生大概是自詡其學術認知超越所有美國疾病管制及預防中心、世界衛生組織的眾多專家們。


3. Bernard Dalbergue最嚴重的指控是專家與藥廠勾結串通,但從常識來看,世界衛生組織與美國疾病管制及預防中心做出疫苗有效並安全的結論的專家們,總數大概至少數百名吧,難道這些專家都接受賄賂?有什麼專家願意這樣賤賣一生的名譽?現在數十個國家都建議青少年女性常規接種疫苗(註:有些國家建議兩性都接種),難道那些國家的專家也都無法判斷學術真偽?如果疫苗真有問題,以後發生訴訟的賠償問題絕對會讓藥廠倒閉,哪一家公司敢掩飾真相一意孤行?

人類乳突病毒疫苗上市以來,已經受到很多質疑。這是因為疫苗接種者太多,一定會有許多時間巧合的事件。過去的很多質疑,現在都被當作笑柄。英國的權威醫師Wakefield氏,因為不當質疑麻疹-腮腺炎-德國麻疹疫苗而身敗名裂,並被當作疫苗安全與醫學倫理的負面教材。這次法國醫師的言論,又是同一類事例。

有人戲稱世界上有「四大不可信」,包括英國研究、大陸製造、台灣媒體、韓國起源,以後可能要多個「法國專家」。

 

2013年6月13日世界衛生組織對人類乳突病毒疫苗安全性專家會議的結論

GACVS Safety update on HPV Vaccines
Geneva, 13 June 201

(http://www.who.int/vaccine_safety/committee/topics/hpv/130619HPV_VaccineGACVSstatement.pdf)

摘要:兩種人類乳突病毒疫苗均無證據顯示有安全性的問題。

At its meeting on 13 June 2013, GACVS reviewed updated information about the safety of HPV vaccines. The last review was conducted in June 2009. GACVS noted at the time that accumulating evidence on the safety of HPV vaccines was reassuring and that studies on HPV immunization had been initiated, along with capacity-building for adverse events monitoring. GACVS places a high priority on the ongoing collection of high-quality safety data in settings where the vaccine is being introduced.


In the past 4 years, safety data continued to accumulate as countries have initiated or expanded their immunization programs. The GAVI Alliance has also begun taking steps to make HPV vaccine available to women in developing countries where the burden of cervical cancer is considerable. To date, some 175 million doses of HPV vaccines have been distributed. A review of adverse events reported to the US Vaccine Adverse Event Reporting System following the distribution of over 23 million doses was published in 2009 (Slade 2009). Many countries were HPV is licensed now have considerable post-marketing data and no concerns have been identified.. The manufacturers of currently available vaccines have developed pregnancy registries and are maintaining long term safety studies in conjunction with efficacy.
The Committee reviewed data from the United States, Australia, Japan and the manufacturers of Cervarix® (GlaxoSmithKline) and Gardasil® (Merck). Updates from the United States included an extension of the spontaneous reports to VAERS since the published review in 2009 as well as completed and planned studies from the Vaccine Safety Datalink. In Australia a new program targeting males started in February 2013 and data are just becoming available.


Data from all sources continue to be reassuring about the safety of the two vaccines.


The data from VAERS now includes over 50 million doses distributed since 2006 and the profile has not changed significantly since the review in 2009. Reported adverse events not identified at the time of the first review, namely syncope and venous thromboembolism (VTE), were further investigated. For syncope, it continues to be reported but remains an event with a plausible relationship given the population and settings under which HPV vaccine is given. Adherence to a 15-minute observation period following vaccination has thus been strengthened as a recommendation. For VTE, while a rapid cycle analysis in the VSD did not find an increased risk, this is further being investigated with appropriate control for confounders such as oral contraceptive use, smoking and other risk factors in this population. Similarly, the VSD did not find any increased risk of Guillain-Barré syndrome or stroke.


In Australia, safety surveillance has been enhanced and the expert group continues to look at reported events. To date, with almost 7 million doses distributed, the previously investigated concern regarding an increased incidence of anaphylaxis was not confirmed. Following the extension of the vaccination program in males and enhanced surveillance since February 1 2013, preliminary results show the safety profile of Gardasil as similar to the profile among females.


The experience in Australia also provides useful lessons for countries introducing new vaccines in this age group, especially when vaccines are administered in a school based vaccination settings. In May 2007, soon after the introduction of the school-based program, 26 of 720 girls vaccinated at a girls’ school developed symptoms including dizziness, palpitations, syncope or collapse, weakness, and aphasia. Four were transported by ambulance to hospital where further clinical evaluation found no organic basis for the reported symptoms. This cluster of adverse events was determined to be a result of a psychogenic response to vaccination. The event generated substantial media interest and public concern in Australia. (Buttery 2008, Gold 2010). Such cases require a prompt and through medical evaluation to establish a diagnosis and then an assessment of the relationship, if any, to the vaccine or vaccination as well as a proactive approach to communication, employing risk communication principles.


Surveillance from the two manufacturers found no signals that suggest a need for revisions to product labelling. Both have maintained surveillance of pregnancy outcomes following inadvertent vaccination during pregnancy. Detailed analyses of results have not found any new adverse outcomes related to HPV vaccination. For Gardasil, long term follow-up has now extended to over 8 years in the longest cohort, and no significant increase in newly diagnosed health events have been identified among those vaccinees. Updated analyses of the pregnancy registry have also been reassuring in that no adverse pregnancy outcomes have been observed beyond background expected rates. For Cervarix, the data have been similarly reassuring regarding pregnancy outcomes and specific events of interest such as immune mediated diseases. Risk of syncope and anaphylaxis have been added to the label to warn of these potential events, the former being also possibly related to conditions around the vaccination experience itself.


Finally, cases of complex regional pain syndrome (CPRS) were reported from Japan where over 8 million doses of HPV vaccines have been distributed. CPRS is a painful condition that emerges in a limb usually following trauma. Cases have been reported following injury or surgical procedures. It remains of unknown etiology and may occur in the absence of any documented injury. CPRS following HPV vaccines has received media attention in Japan with 5 reported cases most of which seem not compatible with typical CPRS cases. Review by an expert advisory committee could not ascertain a causal relationship to vaccination given lack of sufficient case information and in many cases could not reach a definitive diagnosis. While these are under investigation, Japan has continued to provide HPV vaccine in their national program.


In summary, 4 years after the last review of HPV vaccine safety and with more than 170 million doses distributed worldwide and more countries offering the vaccine through national immunization programs, the Committee continues to be reassured by the safety profile of the available products. Anaphylaxis and syncope, outcomes previously identified as concerns, have been addressed through further studies and appropriate revisions were made to the products labeling. Serious adverse events that have been reported as potential signals have been investigated in more detail, including Guillain-Barre Syndrome, seizures, stroke, venous thromboembolism, anaphylaxis, and other allergic reactions – many using rapid cycle analysis in the VSD in the United States. Surveillance of pregnancy outcomes among women inadvertently vaccinated during pregnancy through spontaneous reports and registries have not detected any adverse outcomes above expected rates.


The cases of chronic pain being reported from Japan deserve specific mention. To date there is little reason to suspect the HPV vaccine, given its growing use worldwide in the absence of a similar signal from elsewhere. Recognizing the public concerns voiced, the Committee urges careful documentation of each case and a thorough search for a definitive diagnosis by medical specialists in order to best guide treatment. A timely clinical assessment and diagnosis of each case followed by appropriate treatment is therefore essential.
_____________________________
Buttery JP, Madin S, Crawford NW, Elia S, La Vincente S, Hanieh S, Smith L, Bolam B. Mass psychogenic response to human papillomavirus vaccination. Med J Australia 2008;189(5):261-262


Gold MS, Buttery J, McIntyre P. Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance. Sexual Health 2010;7:320-324


Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009 Aug 19;302(7):750-7. doi: 10.1001/jama.2009.1201

 

美國疾病管制及預防中心對人類乳突病毒疫苗安全性的評論

(http://www.cdc.gov/vaccinesafety/vaccines/HPV/index.html)

Approximately 79 million Americans are infected with human papillomavirus (HPV), and approximately 14 million people will become newly infected each year. Some HPV types can cause cervical, vaginal, and vulvar cancer among women, penile cancer among men, and anal and some oropharyngeal cancers among both men and women. Other HPV types can cause genital warts among both sexes. Each year in the United States an estimated 26,000 new cancers attributable to HPV occur, 18,000 among females (of which 11,500 are cervical cancer) and 8,000 among males (of which 5,900 are oropharyngeal cancers).

There are, however, two HPV vaccines available (Gardasil® and Cervarix®) which protect against the types of HPV infection that cause most cervical cancers (HPV types 16 and 18). Both vaccines should be given as a three-shot series. Clinical trials and post-licensure monitoring data show that both vaccines are safe.

 

相關文章:

子宮頸癌與人類乳突病毒疫苗
子宮頸癌非關不潔 疫苗才能防範未然 (2007.11.29)
10歲接種子宮頸癌疫苗? 20歲恐要補打 (2008.8.13)
下一頁
本站提供的健康資訊為一般性的參考資料,生病時應該讓醫師親自診視才能得到最適當的醫療。

網站外觀改版:2003.10.01

Copyright(C) 台大醫院小兒部李秉穎醫師
上次更新:2016年09月08日
台灣健康資訊網

(TMN) Since June 09, 2002

 

No. of page hits since March 22, 2012

free counters